Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Santaris Pharma Partners with Bristol-Myers Squibb

Published: Wednesday, April 24, 2013
Last Updated: Wednesday, April 24, 2013
Bookmark and Share
Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb to discover and develop novel RNA-targeted medicines.

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10 million, up to $90 million in potential milestone payments per product and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.

Announcing the alliance, President and CEO of Santaris Pharma, Henrik Stage, said: "We are delighted to welcome Bristol-Myers Squibb as a new partner. This strategic alliance further consolidates Santaris Pharma’s leadership in the field of oligonucleotide therapeutics."

Dr Henrik Ørum, Santaris Pharma’s Chief Scientific Officer and VP Business Development commented: "We are proud and honored that Bristol-Myers Squibb has chosen Santaris Pharma as their partner. We are confident that the unique features of the LNA Drug platform can achieve clinical breakthroughs and look forward to working closely with the Bristol-Myers Squibb team."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santaris and miRagen Expand Partnership in the Field of Drugs Against microRNAs
miRagen receives license to develop a further six LNA drugs.
Wednesday, January 16, 2013
Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule
Santaris announces completion of the delivery of six cancer target drug candidates to its collaboration partner Enzon.
Tuesday, April 28, 2009
Santaris Pharma Begins Human Clinical Testing of the World’s First Medicine Targeted at a Human microRNA
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection.
Wednesday, May 28, 2008
Nature Publishes Study by Santaris Pharma Scientists and Collaborators
The paper demonstrates microRNA silencing in non-human primates, providing a validation of Santaris Pharma’s clinical program to develop a LNA-based therapeutics.
Friday, March 28, 2008
Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation
Santaris Pharma has been awarded the grant towards the development of the first ever drug targeted against a human microRNA.
Wednesday, July 04, 2007
Santaris Pharma Raises EUR 40 M of new Equity
The funds will enable the further development of Santaris Pharma’s platform for LNA-based human therapeutics.
Friday, March 17, 2006
Scientific News
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Developing Novel Ear Infection Treatments
Research team engineers antibiotic gel for treating middle ear infections.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!